New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
08:17 EDTSNY, MACKMerrimack completes enrollment in Phase 2 study of MM-121 in collaboration with Sanofi
Merrimack Pharmaceuticals (MACK) announced that the last patient has been enrolled in a Phase 2, open-label, randomized clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum refractory advanced ovarian cancers. MM-121 is being developed in collaboration with Sanofi (SNY).
News For MACK;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
08:28 EDTSNYSanofi has a conference call hosted by JPMorgan
Subscribe for More Information
08:16 EDTSNYPieris Pharmaceuticals achieves payment milestone in Sanofi collaboration
Subscribe for More Information
November 29, 2015
19:37 EDTSNYSanofi working with Lazard to explore sale of animal health unit, Reuters says
Lazard (LAZ) is working with Sanofi (SNY) to prepare a sale or listing of the company's Merial animal health division, which could value the unit at up to $12.7B, reports Reuters, citing sources. The investment bank is expected to land the lead advisory role for the potential deal, sources told Reuters, which added that the sale would play a "pivotal role" in getting Sanofi "back on track." Reference Link
November 24, 2015
05:23 EDTSNYSanofi, Regeneron announce Praluent ODYSSEY OUTCOMES trial enrollment complete
Subscribe for More Information
November 23, 2015
08:03 EDTMACKMerrimack and Baxalta announce publication of ONIVYDE NAPOLI-1 study
Subscribe for More Information
November 20, 2015
06:09 EDTSNYSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 18, 2015
08:11 EDTSNYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use